Swipe tables sideways to see all columns.
Research findings
Comparative structure study
The largest recorded industry, Biomedicine, contains 72 records (91.1% of this 79-record cohort). The remaining cohort contains 7 records. The comparison concerns archive composition.
The recorded sub-industry label Advanced medical devices accounts for 29.1% here (23/79), compared with 23.4% in the parent set (321/1,373), an absolute gap of 5.7 percentage points.
17/79 companies link to pages with existing source-supported excerpts (21.5% of the cohort). The other 62 records remain usable for archive composition, but do not support new operating case studies.
| Company cohort | Directly linked pages | Share of public archive | Archive date |
|---|---|---|---|
| 79 | 79 | 0.4% | 2026-10-16 |
An ID-deduplicated archive snapshot, not the whole market, current recognition or operating results.
Comparable sets and compositional differences
The parent set, Biomedicine and medical devices / Complete systems and use-case applications, contains 1,373 records. This cohort contributes 79 (5.8%); 1,294 records remain after excluding it.
The parent set, Shanghai, contains 1,131 records. This cohort contributes 79 (7.0%); 1,052 records remain after excluding it.
| Category | Cohort count/base | Reference: Biomedicine and medical devices / Complete systems and use-case applications | Gap (pp) | Representation ratio | Rest count/base |
|---|---|---|---|---|---|
| sub-industry · Advanced medical devices | 23/79 · 29.1% | 321/1,373 · 23.4% | +5.7 | 1.25 | 298/1,294 |
| sub-industry · Biomedicine | 33/79 · 41.8% | 643/1,373 · 46.8% | -5.1 | 0.89 | 610/1,294 |
| industry · Biomedicine | 72/79 · 91.1% | 1,292/1,373 · 94.1% | -3.0 | 0.97 | 1,220/1,294 |
Ratio of label participation, not market share; multi-label counts overlap.
Excluding this cohort, the recorded sub-industry label Advanced medical devices covers 298/1,294 remaining records (23.0%), an absolute gap of 6.1 percentage points from this cohort.
Concentration and cross-sectional structure
The full industry distribution has 4 labels; the top 3 contain 78/79 records (98.7%).Other known labels contain 1 records.
For 79 records with known labels, the effective category count is 1.2, versus 4 actual labels. Definitions and scope are in the methodology.
| Recorded label | Records | Share of cohort |
|---|---|---|
| Biomedicine | 72 | 91.1% |
| Next-generation information technology | 3 | 3.8% |
| Advanced equipment | 3 | 3.8% |
| Advanced chemicals | 1 | 1.3% |
Record counts do not rank supply capability or economic size.
Evidence coverage and strength of conclusions
| Record field | Non-empty/cohort | Completion |
|---|---|---|
| Company name | 79/79 | 100.0% |
| reporting jurisdiction | 79/79 | 100.0% |
| industry | 79/79 | 100.0% |
| Recorded products | 79/79 | 100.0% |
| sub-industry | 79/79 | 100.0% |
| Chain labels | 79/79 | 100.0% |
Non-empty fields are not necessarily accurate or supported by originals.
| Scope of source support | Count |
|---|---|
| Profiles with source-supported excerpts | 17 |
| Distinct corresponding companies | 17 |
| Reviewed Chinese/English paragraph pairs | 17 |
Counts concern existing reviewed bilingual excerpts, not re-certification of originals or entire reports.
| Transparent rule reminder | Records | Cohort share |
|---|---|---|
| Only generic operations vocabulary remains | 1 | 1.3% |
A rule hit prioritises review; it does not establish that the entire field is wrong. One record can trigger several rules.
Intersection with 2026 local lists
14 of this cohort’s 79 records link through existing company-ID mappings to 2026 lists from all jurisdictions (17.7%). This intersection measures list linkage, not successful recognition or company growth.
| Observation set | List records | New-applicant records | Review records | Mapped company IDs |
|---|---|---|---|---|
| National list records linked to this cohort’s IDs | 14 | 1 | 13 | 14 |
List rows and company IDs are separate counts, not new firms or final recognition.
Stored 2026 local-recommendation records, sources and stage definitionsRelated provincial study
The 2025 macro context for Shanghai uses a different denominator from this cohort.
Shanghai Company Archive StudyRecorded roles and delivery checks
Related studies and shared records
Shared records with Shanghai / Biomedicine Company Structure Study: 72; records in this cohort but outside that set: 7. The intersection/union ratio is 46.8%, a measure of label overlap rather than business collaboration. Read comparison
Shared records with Shanghai Company Structure Study: 79; records in this cohort but outside that set: 0. The intersection/union ratio is 7.0%, a measure of label overlap rather than business collaboration. Read comparison
Company samples and record links
| Company | Jurisdiction | Recorded industry |
|---|---|---|
| ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Shanghai | Biomedicine |
| Shanghai Cell Therapy Group Co., Ltd. | Shanghai | Biomedicine |
| Shang Hai Sheng Nong Pesticide. Co., Ltd. | Shanghai | Biomedicine |
| Shanghai Upper Bio-Tech Pharma Co., Ltd. | Shanghai | Biomedicine |
| Shanghai Xinwei Medical Technology Co., Ltd. | Shanghai | Biomedicine |
| Biocompounds Pharmaceutical Inc. | Shanghai | Biomedicine |
| Shanghai Tissuebank Diagnositics Co., Ltd. | Shanghai | Biomedicine |
| Shanghai NCC Electronic Co., Ltd. | Shanghai | Advanced equipment |
Stable-ID samples, not rankings; metrics use the full cohort.
Directly related profiles and reports
| Page | Presentation |
|---|---|
| ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Company data profile |
| Shanghai Cell Therapy Group Co., Ltd. | Company data profile |
| Shang Hai Sheng Nong Pesticide. Co., Ltd. | Company data profile |
| Shanghai Upper Bio-Tech Pharma Co., Ltd. | Company data profile |
| Shanghai Xinwei Medical Technology Co., Ltd. | Company data profile |
| Biocompounds Pharmaceutical Inc. | Company report page |